-
New drug for cervical cancer! TF Targeted Antibody Drug Couple (ADC) tisotumab vedotin is showing strong results and will be available on the market!
Time of Update: 2020-10-06
results published at the conference showed that tisotumab vedotin, as a single drug therapy, has significant efficacy and provides objective relief with clinical significance and long-lasting: total remission rate (ORR) of 24%, medium remission duration (DOR) of 8.3 months, and controlled safety.
-
A major breakthrough in first-line treatment of liver cancer! Roche's cancer immunization programme Tecentriq and Avastin (Tai Sanqi and Avetin) is about to be approved by the European Union!
Time of Update: 2020-10-06
!--, 22 September 2020 // -- Roche has announced that the European Medicines Agency (EMA) Commission on Human Pharmaceutical Products (CHMP) has issued a positive review recommending approval of anti-PD-L1 therapy Te Centriq (Tai Sanqi, generic name: atezolizumab, atilijutatin monoanti) in a joint Avastin (Avistin, generic name: bevacizumab, beva bevajuumab) is used to treat adult patients with non-excisive or metastatic hepatocellular carcinoma (HCC) who have not been systematically treated in the past.
-
The correlative clotting disorder and micro blood clot formation in patients with COVID-19 developed in patients with glioma.
Time of Update: 2020-10-06
The Matthew Pun, a medical science specialist training program at the University of Michigan School of Medicine in the United States, and others reported in Acta Neurologica in June 2020 that a case of thalesta-high-level glioma was associated with COVID-19-related clotting disorder in patients with extensive micro blood clot formation in the tumor.
-
The treatment of invasive pituitary adenoma with termoamine.
Time of Update: 2020-10-06
recently, european guidelines for the diagnosis and treatment of invasive pituitary adenomas have used tymoamine as a first-line chemotherapy drug for pituitary cancer.
-
Roche Avastin (bevacizumab injection) glioblastoma indication approved, bringing new treatment options for Chinese patients
Time of Update: 2020-10-06
On September 21, 2020, Roche announced that China's State Drug Administration (NMPA) had approved the treatment of Avastin ® (Avastin; generic name: bevasta monoantitic injection) for adult patients w
-
Immunotherapy provides long-term survival benefits for more patients with esophageal cancer.
Time of Update: 2020-10-06
Professor Shen Lin said that compared with other types of cancer, there has been no breakthrough in treatment and survival improvement of esophageal cancer for decades, and that in recent years the success of immunotherapy in the treatment of esophageal cancer has broken through this "bottleneck", immunotherapy combined chemotherapy or other therapies will provide long-term survival benefits for more patients with esophageal cancer.
-
A major breakthrough in first-line treatment of liver cancer! Roche Tecentriq and Avastin (Tai Sage and Avastin) Japan was approved and China entered priority review!
Time of Update: 2020-10-05
!--,2020 / -- Chugai Pharma, a Japanese pharmaceutical company controlled by Roche, recently announced that Japan's Ministry of Health, Labour and Industry (MHLW) has approved anti-PD-L 1 therapy Tecentriq (Tai Sanqi, generic name: atezolizumab, atilijutatin) in combination with Avastin (Avivin, generic name: bevacizumab, beva bead monoantitor) for the treatment of patients with non-extinct hepatocellular carcinoma (HCC) who had not previously received systematic treatment.
-
Yu Jinming: Top 10 Challenges of Cancer Immunotherapy.
Time of Update: 2020-10-05
many anti-tumor immune nodes, the best immunotherapy in the future is not a single therapy, the combination of treatment is still not enough to overcome metastasis non-small cell lung cancer resistance.
-
China's gastroesoesoesic reflow patients more than 100 million! Long-term insocrement increases the risk of cancer, you can't take it for good.
Time of Update: 2020-10-05
the cause of gastroesoesoesal reflow normally, after we eat, the food goes down the eso pipe into the stomach, and it goes up and down.
gastroesophal reflow if not treated for a long time, gastric acid fluid irritation to the esophalus will also be long-term.
-
FDA awards Disitamab Vedotin (RC48) "breakthrough therapy" for the treatment of urinary endocrine cell carcinoma
Time of Update: 2020-10-05
Pharmaceutical Company RemeGen announced today that the U.S. Food and Drug Administration (FDA) has awarded the new humanized anti-HER2 antibody drug co-ed (ADC) Disitamab Vedotin (RC48) the "breakthrough therapy title." Disitamab Vedotin (RC48) is expected to be used as a second-line therapy for HER2-positive patients with localized advanced or metastatic genitourinary endocrine cell carcinoma (UC), who have previously received chemotherapy with platinum.
-
A study of the heavyweight highlights that Nature magazine had to look at in September.
Time of Update: 2020-10-05
: Uncovering the molecular mechanisms of PARP enzymes to repair fractured DNA strands of cancer cells promises to help develop new targeted anticancer therapies doi:10.1038/s41586-020-2725-1 In a recent study published in the international journal Nature, scientists from St. Jude Children's Hospital and others revealed the structure of PARAP enzymes that break and repair double-stranded DNA, suggesting that PARP2 can fill the gap and connect two broken DNA ends.
-
CSCO Yu Zhentao: Research and prospect of new complementary treatment of esophageal cancer.
Time of Update: 2020-10-05
The history and status of new auxiliary treatment of esophageal cancer in China has been carried out for many years, the earliest relevant research is preoperative radiotherapy, 92 Chinese Academy of Medical Sciences Cancer Hospital published a retrospective analysis of more than 1000 cases, the results show that preoperative radiotherapy increased R0 excision rate, the upper part of esophageal cancer patients from preoperative radiotherapy significantly benefited.
-
Yan Ying: Advanced breast cancer anti-HER2 reasonable stratization treatment.
Time of Update: 2020-10-05
Anti-HER2 targeted therapy drug stratification Anti-HER2 targeted therapy drugs can be divided into two categories according to the mechanism of drug action: one is monoclonal antibody class, includin
-
Colorectal cancer immunotherapy! The Opdivo-Yervoy combination was approved in Japan to treat patients with high microsatellital instability (MSI-H)!
Time of Update: 2020-10-05
September 27, 2020 // -- Ono Pharmaceuticals and Bristol-Myers Squibb K.K., the Japanese subsidiary of Bristol-Myers Squibb K.K., have jointly announced that Japan's Ministry of Health, Labour and Labour (MHLW) has approved the anti-PD-1 therapy Opdivo (Eu Divo, generic name: nivolumab, navudan anti-CTLA-4 therapy Yervoy (ipilimumab, iplimumma), used to treat patients with advanced condition after chemotherapy, high microsatellita instability (MSI-H), non-excisive late stage or relapsed colorectal cancer.
-
HER2-positive stomach cancer first ADC drug! The first three total Enhertu approved: significantly prolonged patient survival, will redefine gastric cancer treatment!
Time of Update: 2020-10-05
!--., September 26, 2020 // -- Daiichi Sankyo recently announced that Japan's Ministry of Health, Labour and Industry (MHLW) has Approved HER2 Targeted Antibody Association Drug (ADC) Enhertu (fam-trastuzumab deruxtecan, DS-8201) for the treatment of HER2-positive non-removable advanced or relapsed gastric cancer patients.
-
Nat Commun: Radiogenomics features reveal infigenesic traits associated with breast cancer survival.
Time of Update: 2020-10-05
Recently, researchers published a paper in the journal Nature Communications, hypothesically, that unsealed de-regeneration of gene expression spectrum could reveal genomic subclonals that affect cancer-related biological function and patient survival, and that radiogenomic features at the imaging level could capture significant potential tumor heterogeneity at the molecular level.
-
Bio Valley recommendation: September must-see heavyweight study Top10.
Time of Update: 2020-10-05
Doi:10.1038/s41422-020-0390-x In a recent study published in the international journal Cell Research, scientists from the Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences and the University of Hong Kong found that SARS-CoV-2 may infect human nerve cells and brain-like organs.
-
Focus on the whole process, the first Cancer Management Forum with love set sail.
Time of Update: 2020-10-05
To enhance the concept of disease prevention, increase drug access, adhere to the long-term management of the disease Fudan University affiliated oncology hospital oncology administrative deputy director / first ward medical director, CACA and CSCO breast cancer expert committee member Professor Zhang Jian believes that in the era of precision, cancer patients' diagnosis and treatment management is mainly reflected in the process of evidence-based evidence application and personal experience release, that is, to achieve tailor-made.
-
A selection of Blod research on September 24, 2020.
Time of Update: 2020-10-05
IKAROS and CK2 regulate high-risk B-ALL BCL-XL expression and chemotherapy sensitivity https://doi.org/10.1182/blood.2019002655 High-risk type B cell acute lymphoblastic leukemia (B-ALL) is an invasive disease characterized by chemotherapy resistance.
-
Nat Commun: Phase I Clinical Trials: All-Trans-Responsic acid as a target drug for pancreatic cancer substations.
Time of Update: 2020-10-05
, researchers recently published a paper in the journal Nature Communications, using a two-step adaptive continuous reassessment trial design for a phase IB, dose upgrade, and expansion trial for patients with late-stage non-excision of PDAC (n-27), which ATRA uses as a substitit target drug in combination with gemcitabine-nab-yew alcohol chemotherapy.
